HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintains a $22 price target.

June 01, 2023 | 2:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Esperion Therapeutics receives a reiterated Buy rating from HC Wainwright & Co. analyst Joseph Pantginis, with a maintained $22 price target.
The reiterated Buy rating and maintained $22 price target by HC Wainwright & Co. analyst Joseph Pantginis is a positive signal for Esperion Therapeutics. This reaffirms the analyst's confidence in the company's potential, which could lead to increased investor interest and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100